Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nippon Shinyaku Seeks Uptravi Use in Pediatric PAH in Japan
April 17, 2024
- Lagevrio’s Smaller Tablet Version Filed in Japan: MSD
April 17, 2024
- Moderna to File mRNA RSV Vaccine in Japan within 2024: Exec
April 17, 2024
- 80%-Plus Doctors Seek In-Person Meetings with Reps: Lilly Survey
April 16, 2024
- Meiji Reaffirms 2028 Launch Plan for New Vaccine Site as METI Grants Finalized
April 16, 2024
- Nxera Grants Pivlaz’s Korean Commercial Rights to Handok
April 16, 2024
- Vabysmo Set for 2025 Filing for Angioid Streaks after Japan Trial Success
April 16, 2024
- Xofluza Approved for Pediatric Use in Taiwan: Shionogi
April 16, 2024
- Fujifilm to Invest 180 Billion Yen to Bolster Biologic CDMO Biz in North America
April 15, 2024
- Astellas Slashes FY2023 Profit Forecasts on Gene Therapy Impairment Loss
April 15, 2024
- Takeda Files 2-Dose Vial Version of Novavax COVID Vaccine
April 15, 2024
- MSD Files Keytruda Plus Chemo for Endometrial Cancer in Japan
April 15, 2024
- Wholesaler Purchase Prices of Unprofitable Drugs on Upward Trend after FY2024 Revision
April 12, 2024
- Japan Autoimmune Drug Market Likely to Top 1 Trillion Yen in 2033: Fuji Keizai
April 12, 2024
- Smallpox Drug TPOXX Filed in Japan after Govt Request
April 12, 2024
- Moderna, Tohoku Biobank Start Epidemiology Study on Latent Viruses
April 12, 2024
- ASKA’s Birth Control Pill Makes Mark in Japan PIII Study
April 12, 2024
- Moderna Plots Successive Launches in Japan, Updated COVID Jab by Fall: Medical Chief
April 11, 2024
- GSK, Nagasaki University Begin Large-Scale Epidemiological Study on RSV
April 11, 2024
- Teijin Out-Licenses Narcolepsy Drug to France’s Bioprojet
April 11, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…